Alzheimer's treatment is finally moving

For decades, Alzheimer's research felt stuck. Now scientists are making genuine breakthroughs in detection and treatment that are changing how doctors approach the disease.

Two drugs now slow cognitive decline

Lecanemab and donanemab, approved in 2023, are the first treatments in decades that can actually slow Alzheimer's progression for people with mild cognitive impairment. They work by targeting amyloid plaque in the brain.

These drugs have real limits

The medications only work for mild cognitive impairment, not advanced disease. They slow decline but don't stop or reverse it, and they carry risks including brain bleeds.

“You're still getting worse, you just get worse more slowly.”

The pipeline is getting stronger

Researchers are moving beyond the amyloid hypothesis to target tau proteins and inflammation. New drugs in clinical trials aim to slow disease better than current medications.

Tau-targeting drugs show promise

Biogen's diranersen reduced tau and improved cognitive symptoms in preliminary trials. Eisai has another tau drug in early safety testing. Both could offer better outcomes than current treatments.

Scientists finally agree on mechanisms

Instead of fighting over which theory is right, researchers now accept that amyloid, tau, and inflammation all play roles. This consensus opens more targets for new drugs.

“There's a kind of general democratization. There are multiple promising mechanisms.”

Reversal may be possible eventually

In the long term, combination treatments targeting different mechanisms could potentially reverse Alzheimer's. But experts say meaningful treatments that stop disease progression are closer in the next couple of years.

Early detection is now critical

New blood tests can detect tau proteins and predict Alzheimer's risk with impressive accuracy. Catching the disease early gives patients more time before symptoms worsen.

Menopause may accelerate disease

Research suggests menopause could be an accelerant for Alzheimer's progression, making it an important intervention point for at-risk women.

The future of prevention is clear

As people age, blood tests will identify those at higher risk. They can then take medications like lecanemab or donanemab to delay or prevent symptoms from starting.

“We couldn't get the right people at the right time early on, and now we can.”

GLP-1 drugs may help prevention

Ozempic and similar drugs didn't slow disease in people already showing symptoms, but they may prevent Alzheimer's by reducing inflammation and improving vascular health decades before it starts.

Obesity control could be preventative

Chronic inflammation, obesity, and poor vascular health accelerate cognitive aging. If GLP-1 drugs keep obesity in check across the population, their biggest impact on Alzheimer's may be indirect.

Major research initiative launches

The Alzheimer's Association announced a $100 million project to study whether lifestyle changes plus GLP-1 medication can reduce dementia risk in at-risk older adults.

You can take action now

Talk to your doctor about blood tests and medications like lecanemab and donanemab. You may also qualify for clinical trials, where researchers need participants to advance treatment development.

Science funding faces political threat

The Trump administration and Health Secretary Robert F. Kennedy Jr. are cutting research grants, including $15 million in dementia studies on discrimination and brain health.

Politicization could wreck progress

Experts warn that politicizing the grant process threatens American science and could prevent the breakthroughs that are now within reach.

“The biggest threat is outside the science. There's deep concern that this politicization of the grant process will essentially wreck American science.”

Vote to protect research

Support lawmakers who fund and defend science. Advances in Alzheimer's treatment don't happen on their own. Society needs to get involved.

“You can vote for people who will fund and support science as an endeavor.”